our pipeline
The science of Tumor Treating Fields has the potential to extend beyond glioblastoma. Treatment with TTFields has shown a consistent antimitotic effect in our preclinical and clinical research over the last 16 years.
We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which TTFields exert their effects within dividing cancer cells. Our research shows that TTFields can have an anti-mitotic effect in over 15 different solid tumor types in culture and in eight in vivo tumor models, including some of the most aggressive forms of cancer. We are committed to advancing the science of TTFields across a broad spectrum of solid tumors and bringing our treatment to cancer patients who can benefit from our therapy.
Novocure clinical pipeline
as of February 2017
|
Pre-clinical
|
Phase II
|
Phase III
|
FDA Approved
|
|
|---|---|---|---|---|
| Recurrent Glioblastoma | ||||
| Newly Diagnosed Glioblastoma | ||||
| Brain Metastasis | ||||
| Non-small Cell Lung Cancer | ||||
| Ovarian Cancer | ||||
| Pancreatic Cancer | ||||
| Mesothelioma | ||||
|
Trial ongoing
Trial complete
|
||||
we also have pre-clinical data for Tumor Treating Fields in these areas:
Pre-clinical
- breast cancer
- cervical cancer
- colorectal carcinoma
- gastric adenocarcinoma
- hepatocellular carcinoma
- malignant melanoma
- renal adenocarcinoma
- urinary transitional cell carcinoma
- small cell lung cancer
clinical trials
Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types.
We sponsor clinical trials of Tumor Treating Fields in several cancer types. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov.
additional research
Additional investigator-sponsored trials are also ongoing. For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov.
This information is for medical, and scientific and educational purposes only. TTFields are experimental for the treatment of patients with brain metastases, ovarian carcinoma, pancreatic adenocarcinoma, mesothelioma and non-small cell lung cancer. TTFields has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Limited by federal law to investigational use only.